-

Allurion Announces Collaboration Agreement with Medtronic to Expand Access to AI-Powered Weight Loss Program

The 12-month sales agency agreement helps expand access to Allurion’s platform in the CEMA region by leveraging Medtronic’s channels

NATICK, Mass.--(BUSINESS WIRE)--Allurion, a company dedicated to ending obesity, today announced a pilot collaboration agreement with Medtronic, a global leader in healthcare technology, to expand access to Allurion’s AI-powered weight loss program through a sales agency agreement in the Central and Eastern Europe, Middle East, and Africa (CEMA) region. The partnership enables Allurion to offer the Allurion Balloon and accelerate utilization of the Allurion Iris Artificial Intelligence (AI) Platform in the management of bariatric surgery patients by leveraging Medtronic channels during the collaboration.

The Allurion Program combines the Allurion Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss with the Allurion Virtual Care Suite, a remote patient monitoring solution powered by the Allurion Iris AI Platform and the company’s proprietary behavior change program. The Allurion Virtual Care Suite is also available to providers as a standalone product to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional.

In February 2023, Allurion announced its intention to go public via a business combination with Compute Health. Medtronic is currently an investor in Compute Health, and this agreement builds upon that existing relationship.

"We are thrilled to join forces with Medtronic to expand access to our weight loss program. Medtronic has exceptional distribution capabilities across a number of different channels that can augment our base business,” said Dr. Shantanu Gaur, Allurion’s Founder and CEO. “We also believe this partnership will help accelerate adoption of our Iris AI Platform as a standalone offering to streamline the management of patients undergoing bariatric surgery and potentially improve outcomes, further cementing our position as a leader in AI and weight management.”

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Contacts

For media inquiries, please contact:

Cedric Damour
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com

Erik Milster
SeriesM PR 
508.740.6125
emilster@seriesmpr.com

Allurion


Release Versions

Contacts

For media inquiries, please contact:

Cedric Damour
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com

Erik Milster
SeriesM PR 
508.740.6125
emilster@seriesmpr.com

Social Media Profiles
More News From Allurion

Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with Minogue Medical Inc., a leading Canadian medical device company specializing in bariatric and obesity care. This new partnership draws upon Minogue Medical’s 40-year experience in the Canadian market and reflects Allurion’s commitment to establishing a new standard of care in obesity management focused on metabolicall...

Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced submission of the fourth and final module of the Pre-Market Approval (PMA) application to the Food & Drug Administration (FDA) and additional, supportive analyses from the AUDACITY Study that meet both of the pre-specified co-primary endpoints. Topline results announced previously showed that the AUDACITY Study met its first co-primary endpoint related to...

Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today presented two new abstracts at the American Society for Metabolic & Bariatric Surgery (ASMBS) 2025 Annual Meeting. This data include findings from a global, real-world experience evaluating body composition outcomes that demonstrate sustained weight loss, significant fat loss, and preservation of muscle mass with the Allurion Program and one of the longest real-wor...
Back to Newsroom